Date: 2012-10-17
Type of information: Fundraising
Company: Apim Therapeutics (Norway)
Investors: Norsk Innovasjonskapital III AS (Norway)
Sarsia Seed (Norway)
Birk Venture (Norway)
Ro Invest (Norway)
Amount:
Funding type: financing round
Planned used: These funds will allow APIM Therapeutics for further preclinical development of its lead compound, ATX-101.
Others: APIM Therapeutics, a preclinical biotech company focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), a validated cancer target implicated in the regulation of cellular responses to various stress signals, has closed a financing round enabling the company to further advance its lead compound, ATX-101, towards IND-enabling regulatory studies. To date, ATX-101 has shown promising activity in several preclinical solid tumor and blood cancer models and is capable of potentiating the action of >15 clinical drugs.
The investment is led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed (Bergen, Norway), Birk Venture and Ro Invest (Oslo, Norway).
APIM Therapeutics was established in 2009 as a result of several years of scientific work at Prof. M. Otterlei\'s laboratory at the Norwegian University of Science and Technology (NTNU). This research has identified a novel therapeutic intervention point relevant for the treatment of a large variety of cancer cells including, among others, bladder cancer and multiple myeloma.
Therapeutic area: Cancer - Oncology
